NCT07099443RECRUITINGN/AThe aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia (CLL), to facilitate access for the National Institute of Health and Medical Research (INSERM) to patients with double-refractory CLL. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent. These samples will first be sent to the Filothèque for temporary storage, and will then be transferred to CRCI²NA (Nantes - Angers Cancer and Immunology Research Center) for analysis with the aim of studying the mechanisms of resistance and response to BTK degraders (BTKd).
No linked publications found in PubMed
Inclusion Criteria: * Patient with confirmed double refractory CLL to both BTKi and BCL-2i, defined as: * Any patient who has received both a BTKi and a BCL-2i, regardless of treatment regimen, and has shown clinical progression either during treatment with both BTKi and BCL-2i, or within 36 months after stopping BCL-2i. * Any patient identified with known biological resistance mutations to BTKi or BCL-2i, regardless of clinical progression. * Patient who has provided informed consent to participate in the study. * Patient covered by a social security health insurance plan Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons.